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Abstract
The pharmacokinetics and the effects of a single intramuscular (IM) dose of alfaxalone on
sedation and cardiopulmonary and echocardiographic variables was studied in dogs. Twelve
healthy adult Beagles (3 females, 9 males) were used in this prospective controlled cross-over
trial. Echocardiography was performed with and without 4 mg kg-1 alfaxalone IM with a week
wash-out interval. Sedation (19-point scale; 0 = no sedation), cardiopulmonary parameters,
blood gas analysis and plasma concentration of alfaxalone were assessed every 5 minutes fol-
lowing the injection (T0). The influence of the alfaxalone plasma concentration and time on
physiological variables was tested using a linear model whereas echocardiographic measure-
ments were compared between conscious and alfaxalone-administered dogs using paired t-
tests. Compared to baseline, alfaxalone administration was followed by an increase in heart
rate (HR) from T5 to T30 and a decrease in mean arterial pressure (MAP) at T10, T25 and
T30, in stroke volume (SV; 15 ± 5 to 11 ± 3 ml; P<0.0001), and end-diastolic volume (EDV;
24.7 ± 5.7 to 19.4 ± 4.9 ml). Cardiac output (CO) and blood gas analysis did not change signifi-
cantly throughout. Mean plasma half-life was 29 ± 8 minutes, volume of distribution was 1.94 ±
0.63 L kg-1, and plasma clearance was 47.7 ± 14.1 ml kg-1 minute-1. Moderate to deep sedation
was observed from T5 to T35. Ten dogs showed paddling, trembling, nystagmus and strong
reaction to sound during the procedure. Although there were no significant changes in CO and
oxygenation, the impact of HR, MAP, SV, EDV alterations requires further investigations in
dogs with cardiac disease.
PLOS ONE | https://doi.org/10.1371/journal.pone.0204553 September 24, 2018 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Cruz-Benedetti I-C, Bublot I, Ribas T,
Fourel I, Vogl C, Dubois C, et al. (2018)
Pharmacokinetics of intramuscular alfaxalone and
its echocardiographic, cardiopulmonary and
sedative effects in healthy dogs. PLoS ONE 13(9):
e0204553. https://doi.org/10.1371/journal.
pone.0204553
Editor: Francesco Staffieri, University of Bari,
ITALY
Received: December 16, 2017
Accepted: August 17, 2018
Published: September 24, 2018
Copyright: © 2018 Cruz-Benedetti et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors received no specific funding
for this work. Dr Ribas is employed by a private
veterinary clinic (Azurvet, Hippodrome, Cagnes sur
mer, France) but participated in the study during
his free time. Therefore, the clinic (Azurvet,
Hippodrome, Cagnes sur mer, France) did not have
any role in the study design, data collection and
analysis, decision to publish, or preparation of the
Introduction
Interpretation of echocardiography in canine patients requires high quality images, which can
only be acquired in calm animals that do not resist physical restraint. In addition, patients pre-
sented for echocardiography may have severe cardiac diseases. A chemical restraint with mini-
mal effect on blood pressure and cardiac output (CO) often becomes necessary to ensure
myocardial oxygenation in these patients [1]. Ideally, interpretation of the echocardiographic
variables should not be affected by sedation. However, most sedative and anaesthetic drugs
(like alpha-2 agonists, acepromazine, ketamine) influence cardiac activity and vascular tone
directly [2].
Alfaxalone in hydroxypropyl beta cyclodextrin, a neuroactive steroid anaesthetic, provides
good short-term anaesthesia with minimal cardiorespiratory effect in unpremedicated dogs at
2–4 mg kg-1 IV [3–5]. According to Kim et al. [6], alfaxalone IV also provides an adequate
sedation for echocardiographic examination with no statistical and clinical significant cardio-
vascular depression in healthy dogs. However, the IV administration route may not be feasible
in aggressive, stressed or sick animals without previous sedation by the oral, intramuscular
(IM) or subcutaneous route. In addition, IM injections can be less time-consuming and expen-
sive than IV injections for which the placement of a catheter is recommended.
Moreover some authors suspected that the rapid alfaxalone IV injection is responsible for
rare cardiorespiratory effects, particularly apnoea [5,7].
Alfaxalone’s hydrosolubility is increased by 375 times due to its excipient hydroxypropyl
beta cyclodextrin [8], which makes its administration IM possible although this route is not
approved in France. The choice of the administration route should be based on safety, efficacy,
patient or clinician preference and pharmacoeconomics [9]. Alfaxalone administered IM
induced dose-dependent neurodepression, lateral recumbency and maintenance of cardiovas-
cular parameters within clinically acceptable limits [10]. Combinations of medetomidine and
butorphanol administered as premedication prior to a subclinical dose of alfaxalone IM were
not recommended in dogs with cardiovascular disease but the role of each drug remained
unclear [11,12]. Alfaxalone in combination with butorphanol, provided a rapid, deep sedation
in cats and induced some changes in echocardiographic measurements that were not consid-
ered clinically significant [13].
To our knowledge, the effect of IM alfaxalone alone on echocardiographic measurements
in dogs has not been studied yet. Similarly, while the pharmacokinetics of IV alfaxalone
administration in dogs have been investigated [14], such data following the IM route remained
unknown. Therefore, the objective of our study was to determine the pharmacokinetics and
dynamics of a single IM dose of alfaxalone and its impact on sedation, cardiopulmonary func-
tion, and echocardiographic measurements in healthy dogs. Deep sedation of approximately
30 minutes, an increase in heart rate (HR), a decrease in arterial blood pressure and respiratory
rate (fR) with no clinically significant modifications in echocardiographic measures were
expected.
Materials and method
Animals
The study was approved (N˚ 1453) by the Ethical Committee of VetAgro Sup (Chairperson Dr
S. Vidal) on 15 December 2014. The study followed the recommendations of the Animal
Research Reporting of In Vivo Experiments (ARRIVE) guidelines [15]. Twelve 2.0 ± 0.6 years
old healthy Beagle dogs, 9 males and 3 females, weighing 9.3 ± 1.7 kg, with a body condition
score of 4 out of 9 (range 3–7), and American Society of Anaesthesiologist physical status
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classification (ASA) 1–2 were included in the study. The sample size was determined by power
analysis of 0.88 for one-sample experimental design to detect a difference in means of 30 beats
minute-1 in HR, considering a standard deviation of 38 and a nominal significance level of
0.05. Dogs were judged to be healthy based on physical examination and on a complete blood
count and serum biochemistry, including troponin I to rule out myocardial cell injury. The
dogs were originated from a laboratory of our institution, where they were housed in groups
with free access to an outdoor area. Their health status was monitored daily by a veterinarian
(ICCB) and the study was performed in the Veterinary School of our institution.
Study design
In this prospective controlled cross-over experimental study the order in which animals
underwent the study was randomly assigned by submitting the animal chip numbers to a web
software (https://www.random.org/lists/) and attributing letters from A-L to the animals in
the order assigned by the software. The study design is shown in Fig 1.
Dogs were fasted for 6 hours prior to be brought to the examination room. Each animal
was given at least 30 minutes to adapt to the new environment before their behaviour was
scored with a simple descriptive score (1 = calm, 2 = stressed/cooperative, 3 = stressed/aggres-
sive, 4 = very aggressive). Baseline measurements of physiological variables were registered
and a 4 ml venous blood sample was withdrawn from the jugular vein.
Echocardiography in conscious dogs. After a further resting time of at least 30 minutes,
dogs were auscultated by a veterinary cardiologist (MM) and an echocardiographic assessment
in lateral recumbency with a simultaneous lead II electrocardiogram (Vivid I, with 6S phased
array probe, GE Healthcare, France) was performed in accordance with standard recommen-
dations by another cardiologist (IB) to establish baseline values before sedation [16].
Echocardiographic data were recorded by a single blinded third cardiologist (TR) for off-
line measurements. Measurements obtained from R-R interval over three consecutive cardiac
cycles were averaged and compared to control values. Pulse rate was also registered indepen-
dently every 5 minutes throughout. The echocardiography was always performed in the same
order: 1) right parasternal window: right parasternal four-chamber long-axis view, right para-
sternal five-chamber long-axis view, right parasternal short-axis transventricular and transaor-
tic view, and modified parasternal short-axis view, 2) subcostal view, 3) left parasternal
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0204553.g001
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window: left parasternal four-chamber long-axis view; left parasternal five-chamber long-axis
view and a modified left parasternal short-axis view. The left ventricular posterior wall thick-
ness (LVPW), interventricular septal wall thickness (IVS) and the left ventricular diameter
(LVID) were measured using the M-Mode from a right parasternal transventricular short-axis
view in diastole (d) and systole (s). The shortening fraction (FS) was calculated as a percentage
according to the formula: FS = 100 × (LVIDd-LVIDs)/LVIDd. Left ventricular end-diastolic
(EDV) and end-systolic volumes (ESV) were measured with single plane Simpson’s method
2D-mode still images from a right parasternal four-chamber long-axis view. The ejection frac-
tion (EF) was calculated as a percentage from the formula: EF = 100 × (EDV-ESV)/EDV. The
stroke volume (SV) was calculated as SV = EDV—ESV. The CO was calculated as
CO = HR × SV. A right parasternal short-axis transaortic view was used to measure left atrial
(LA) and aortic (Ao) diameters in early diastole from 2D still images [17] and the LA/Ao ratio
was calculated. Peak pulmonic flow velocity (VPulmmax) was measured with continuous-wave
Doppler from a modified right parasternal short-axis view as previously described [18]. Peak
aortic flow velocity (VAo max) was measured with continuous-wave Doppler from a subcostal
view. Isovolumic relaxation time (IVRT) was measured from a left parasternal five-chamber
view. The peak velocity of the tricuspid regurgitation (TR) and the peak velocity of the pulmo-
nary regurgitation were recorded by continuous-wave Doppler from any view that offered the
highest velocity flow in order to evaluate systolic and/or diastolic pulmonary hypertension
respectively. Mitral inflow was recorded by pulsed-wave Doppler from a left apical four-cham-
ber view and used to estimate the peak velocity of early diastolic transmitral flow (E) and late
diastolic transmitral flow (A) as well as to measure the E-wave deceleration (EDT) time. Mitral
valve annulus velocities were measured from a left apical four-chamber view with Tissue
Doppler Imaging (TDI). In order to measure the peak early diastolic lateral (E’lat), the peak
early diastolic septal (E’sept), the peak late diastolic lateral (A’lat) and the peak late diastolic sep-
tal (A’sept) mitral valve annulus velocities the sample was placed successively on the septal and
the lateral mitral valve annulus. The collected data were used to calculate the following ratios:
E/A, E/E’lat, E/E’sept, E’lat/A’lat, E’sept/A’sept.
Sedation. After completion of the echocardiography, dogs were allowed to rest for an
hour and were then injected 4 mg kg-1 alfaxalone (Alfaxan, 10 mg ml-1, Dechra-Jurox, UK)
intramuscularly (IM). The drug was administered at two injection sites in the caudal lumbar
muscle (T0), since the total volume exceeded 0.25 ml kg-1, which is considered good practice
for injection in one site [19].
Sedation score
Sedation was video recorded and scored using a modified 19-points simple descriptive
sedation scale [20] (0 = no sedation, 10–15 = moderate sedation, >15 = deep sedation; Fig 2)
at baseline and every five minutes following alfaxalone injection until the animal stood up. The
time to lateral recumbency (LRT), time to voluntary first movement (VFMT), time to head lift
(HLT), time to unaided standing (UST), time from lateral recumbency to voluntary first move-
ment (SedT), time from lateral recumbency to unaided standing (DecT) and time from head
lift to unaided standing (RecT) were assessed. Any adverse behaviour, such as paddling,
increased muscular tension and vocalisation were recorded.
Cardiopulmonary data
The HR, respiratory rate (fR), oxyhemoglobin saturation (SpO2), oscillometric non-invasive
blood pressure (NIBP) and rectal temperature (T˚C) were monitored using a pre-calibrated
monitor (Vetcare, B. Braun, Germany) at baseline and every five minutes after alfaxalone
injection until the dog stood up. Arterial blood gas analyses were performed at T+5, T+20, and
T+35.
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Pharmacokinetics
Venous blood (2.5 ml) was sampled at baseline and at 5, 10, 15, 25, 35 and 50 minutes (T+5,
T+10, T+15, T+25, T+35 and T+50, respectively) after injection for measuring the alfaxalone
plasma concentration. Blood was collected in heparinized tubes that were immediately placed
on wet ice and were centrifuged (ca. 21˚C, 2,500 cycles minute-1, 5 minutes) within 30 min-
utes. The plasma was harvested and stored at -70 to -80˚C for later determination of alfaxalone
concentration by protein precipitation [21] followed by liquid chromatography-mass spec-
trometry using an Agilent 1200 series HPLC and 6410B Triple Quadrupole (Agilent Technolo-
gies, Santa Clara, CA, USA). The latter was performed by homogenisation of 50 μL of plasma
(defrosted at ambient temperature) with 200 μL of acetonitrile using a vortex for one minute
followed by centrifugation for 10 minutes at 10,000 cycles minute-1. The supernatant was
retrieved, filtered and then used for plasma concentration dosage. Plasma obtained from the
Fig 2. Modified scale of Gurney et al. [20] used to score sedation in 12 healthy Beagles every 5 minutes from 5
minutes after IM injection of 4 mg kg-1 alfaxalone until they were standing.
https://doi.org/10.1371/journal.pone.0204553.g002
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blood sampled before sedation was used as a control group. This plasma was mixed with differ-
ent quantities of alfaxalone (from 100–2500 ng ml-1) to create a calibration curve.
A mono-compartmental pharmacokinetic method was used to approximate the pharmaco-
kinetic variables for each dog. A semi-logarithmic scale was used to plot the plasma concentra-
tion curve for alfaxalone versus time. A linear trend curve was drawn to extrapolate the plasma
concentration time course from the measured concentration points and its slope was calcu-
lated (ke). The elimination half-life (t1/2) was calculated from the slope: t1/2 = ln2/ke. Alfaxalone
plasma concentration at the time of administration (C0) was estimated from the linear trend
curve and the plasma clearance (Clp) was calculated as follows: Clp = Dose/ C0. The volume of
distribution (Vd) was calculated from the formula: Vd = Clp/ke.
Echocardiography under sedation. One week later, dogs were fasted for 6 hours. They
were then allowed to acclimatise in the examination room for at least 30 minutes before they
were administered 4 mg kg-1 of alfaxalone IM at two injection sites in the contralateral caudal
lumbar muscle compared to the previous week. Five minutes after drug administration, the
dogs were gently restrained for echocardiography. The same cardiologist (IB) performed the
echocardiography of conscious and sedated dogs. The third cardiologist (TR) performed off-
line analysis. Heart rate, MAP, fR and SpO2 were also recorded.
Statistical analysis
Semi-quantitative variables (i.e. body condition scores, behaviour scores, and sedation scores)
and the duration of echocardiography (strongly dependent on animal behaviour) were treated
non-parametrically and were reported as median (range). All other data were presented as
mean ± SD since the Kolmogorov-Smirnov test indicated no significant deviation from a nor-
mal distribution. The plasma concentration measurements were log-transformed after adding
10 to avoid undetermined numbers, i.e., log([alfaxalone]+10). The Bonferroni correction and
the calculation of a local false discovery rate (FDR; q-value) were performed to account for mul-
tiple testing. Using a linear model, the influence of the alfaxalone plasma concentration was
tested on six target variables (HR, MAP, fR, SpO2, T˚C and sedation scores). A one-way
repeated measures ANOVA followed by t-tests (alpha = 0.05/6 = 0.008) was used to detect dif-
ferences between the baseline values of these variables and their values recorded at each of the
six treatment times (T+5 to T+30). Echocardiographic measurements (24 target variables,
where ratios were excluded as composites) were compared between conscious and alfaxalone-
administered dogs using paired t-tests (alpha = 0.05/24 = 0.002); for these variables, a local FDR
was also calculated at a level of 0.01 to compare to the results with the Bonferroni correction.
Results
Data from one dog had to be excluded from the sedation trial since it moved during injection
and the drug was partially administered subcutaneously.
Results of alfaxalone plasma concentration are shown in Table 1 and Fig 3. The mean t1/2
was 29 ± 8 minutes, the Vd was 1.94 ± 0.63 L kg-1 and the Clp of alfaxalone was 47.7 ± 14.1 mL
kg-1 minute-1.
A nearly linear relationship between the logarithm of alfaxalone plasma concentration and
time was observed from T+10 onwards (Fig 4). Alfaxalone plasma concentration influenced
HR (regression coefficient = 7.43, p< 0.001) and the sedation score (regression coeffi-
cient = 2.810, p< 0.001) positively, and fR (regression coefficient = -1.16, p< 0.005) and T˚C
(regression coefficient = -0.13, p< 0.001) negatively. Alfaxalone plasma concentration had no
significant influence on SpO2 (p = 0.97) and MAP (regression coefficient = -2.22, p = 0.03)
after multiple test correction.
Intramuscular alfaxalone for echocardiography in dogs
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Under sedation alone (week I), a significant increase in HR was observed at T+5
(p = 0.003), T+10 to T+30 (p< 0.001); a significant decrease in MAP was observed at T+10
(p = 0.005), T+25 (p = 0.007), and T+30 (p = 0.006); a significant decrease in fR was observed
at T+5 (p = 0.005); and a significant decrease in temperature was observed at all time points, T
+5 (p = 0.004), T+10 to T+30 (p< 0.001). The SpO2 and arterial blood gas values did not
Table 1. Mean (± SD) cardiorespiratory variables, alfaxalone plasma concentration, and median (range) sedation scores following 4 mg kg-1 alfaxalone adminis-
tered intramuscularly in healthy Beagles during sedation alone (week I) and during echocardiography under sedation (week II).
Week I Variables Baseline T+5 T+10 T+15 T+20 T+25 T+30 T+35 T+40 T+45 T+50
HR (beats minute-1) 91 ± 11 119 ± 24 138 ± 27 135 ± 32 137 ± 37 122 ± 28 122 ± 40 - - - -
MAP (mmHg) 104 ± 14 102 ± 17 88 ± 11 93 ± 23 92 ± 9 88 ± 12 88 ± 11 - - - -
fR (breaths minute-1) 26 ± 7 21 ± 7 21 ± 6 22 ± 10 25 ± 13 19 ± 5 23 ± 12 - - - -
SpO2 (%) NA 96 ± 2 96 ± 2 95 ± 4 96 ± 2 96 ± 3 96 ± 3 - - - -
T˚C 38.4 ± 0.3 38.1 ± 0.4 37.7 ± 0.3 37.7 ± 0.4 37.5 ± 0.4 37.5 ± 0.4 37.4 ± 0.5 - - - -
Alfaxalone plasma
concentration (μg ml-1)
0.0± 0.0 2.1 ± 0.6 2.1 ± 0.9 1.5 ± 0.4 - 1.2 ± 0.3 - 1.0 ± 0.3 - - 0.8 ± 0.2
Sedation score 0 [0;1] 14 [3;17] 17 [8;18] 17 [9;18] 17 [6;18] 17 [7;18] 17 [8;19] 15 [5;18] 10 [2;18] 7 [0;15] 5 [0;11]
Week II HR (beats minute-1) 97 ± 13 114 ± 27 126 ± 22 125 ± 24 121 ± 21 119 ± 29 104 ± 13 - - - -
MAP (mmHg) 100 ± 14 87 ± 12 84 ± 12 86 ±16 83 ±11 87 ± 14 81 ±9 - - - -
fR (breaths minute-1) 23 ± 4 18 ± 3 18 ± 3 18 ± 4 18 ± 5 18 ± 3 19 ± 3 - - - -
SpO2 (%) NA 96 ± 1 96 ± 1 96 ± 2 96 ± 2 97 ± 2 98 ± 1 - - - -
HR: heart rate; MAP: mean arterial pressure; fR: respiratory rate; SpO2: oxyhemoglobin saturation; baseline: prior to alfaxalone administration; T+5, T+10, T+15, T+20,
T+25, T+30, T+35, T+40, T+45 and T+50: 5, 10, 15, 20, 25, 30, 35, 40, 45 and 50 minutes after alfaxalone administration, respectively
 indicates a significant difference from baseline values after Bonferroni correction (p< 0.05/6 = 0.0083).
https://doi.org/10.1371/journal.pone.0204553.t001
Fig 3. Median sedation scores and corresponding mean alfaxalone plasma concentration assessed every five minutes after IM administration of 4 mg kg-1
of alfaxalone in 11 healthy Beagles.
https://doi.org/10.1371/journal.pone.0204553.g003
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change significantly throughout (Tables 1 and 2). Under sedation during echocardiography
(week II), a significant increase in HR was observed at T+10 (p = 0.001), T+15 (p = 0.001), and
T+20 (p = 0.005); a significant decrease in MAP was observed at T+5 (p = 0.002), T+10 to T
+20 (p< 0.001), T+25 (p = 0.001), and T+30 (p = 0.002); a significant decrease in fR was
observed at T+5 (p = 0.006), T+10 (p = 0.006), and T+15 (p = 0.008) (Table 1). The HR, MAP
and fR acquired on alfaxalone-administered dogs in week I and II showed a similar trend,
although all values were lower during the second sedation.
The median behavioural score was 1 (1–3). All dogs but one had behaviour scores of 2 or
less and only one dog (J) was aggressive. The dogs were moderately to deeply sedated from T
+5 to T+35. Sedation was considered deep for 20 minutes from T+10 onwards (Table 1).
Fig 4. Boxplot of the log of the plasma concentration of alfaxalone at different time-points after application. Note the nearly linear relationship from T+10
onwards. T+0: alfaxalone administration; T+5, T+10, T+15, T+25, T+35, and T+50: 5, 10, 15, 25, 35, and 50 minutes after alfaxalone administration.
https://doi.org/10.1371/journal.pone.0204553.g004
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While the plasma concentration of alfaxalone was maximal at T+5, the sedation score had not
reached its highest value (Fig 3). Conversely, the plasma concentration of alfaxalone started to
decrease at T+15 while the sedation score was always maximal. There was a 20-minute lag
between the decrease in the sedation score and the decrease in plasma concentration. Trem-
bling or paddling after stimulation, almost exclusively by sound, were noted in 10 dogs (91%).
Three of these dogs presented nystagmus during sedation.
The LRT was 5.4 ± 3.6 minutes, VFMT was 28.9 ± 10.0 minutes, HLT was 31.9 ± 8.0 min-
utes, UST was 48.2 ± 11.7 minutes, SedT was 23.5 ± 12.2 minutes, DecT was 42.8 ±14.1 min-
utes, and RecT was 16.3 ± 8.2 minutes.
Echocardiography
Median duration of echocardiography in conscious and alfaxalone-administered dogs was 37
[22–60] minutes and 27 [24–33] minutes, respectively. All echocardiographic results are dis-
played in Table 3. Concerning the 2D echocardiographic measurements, EDV (p< 0.001) and
SV (p< 0.001) were significantly lower in dogs administered alfaxalone compared to con-
scious dogs. Alfaxalone had no effect on CO, ESV, LA, LA/Ao, Ao, and EF. Regarding the M-
mode echocardiographic measurements, no significant difference was observed in LVIDd,
LVIDs, LVPWd, LVPWs, IVSd, IVSs or in FS. Concerning the Doppler echocardiographic
measurements, significant decreases in E’sept and VAo max (p< 0.001 for both variables) were
observed between conscious and alfaxalone-administered dogs. No significant difference was
observed in E velocity, E/A, EDT, Vpulmmax, A velocity, E’sept/A’sept, IVRT and E/IVRT. A
local false discovery rate was also calculated using 24 variables (excluding the ratios as compos-
ite variables) with a cut-off of 0.01 and obtained the same three variables (EDV, E’sept, and
VAo max) that were significantly different with the Bonferroni correction.
Mild tricuspid regurgitation was present in all dogs. The peak velocity of the TR could be
measured in all dogs but one after sedation because the flow profile was poorly defined in that
dog. Mild pulmonary regurgitation was present in 6 dogs at baseline and in 8 dogs after
Table 2. Mean (± SD) arterial blood gas analysis following 4 mg kg-1 alfaxalone administered intramuscularly in 11 healthy Beagles.
Variables T+5 T+20 T+35
pH 7.43 ± 0.03 7.43 ± 0.03 7.42 ± 0.03
HCO3
- (mmol/L) 22.2 ± 3.3 22.9 ± 3.5 23.0± 3.5
PaCO2 (mmHg) 36.5 ± 4.4 37.3 ± 4.9 38.5 ± 4.9
Anion Gap (mmol/L) 22.8 ± 2.1 22.9 ± 2.4 23.0 ± 2.3
BE (mmol/L) -0.9 ± 2.8 -0.3 ± 3.0 -0.6 ± 3.0
tCO2 (mmol/L) 23.3 ± 3.5 24.1 ± 3.6 24.2 ± 3.6
PaO2 (mmHg) 85.0 ± 15.1 91.8 ± 9.4 88.3 ± 13
tHb (g/dL) 13.0 ± 2.0 12.0 ± 2.7 12.7 ± 2.3
SaO2 (%) 95.5 ± 2.9 95.8 ± 3.1 96.2 ± 3.4
Na+ (mmol/L) 156.4 ± 2.1 157.6 ± 2.0 158.1 ± 2.5
K+ (mmol/L) 3.3 ± 0.5 3.4 ± 0.5 3.2 ± 0.5
Cl- (mmol/L) 114.7 ± 1.3 114.6 ± 2.5 115.2 ± 1.3
PAO2 (mmHg) 97.9 ± 3.9 97.0 ± 5.2 95.5 ± 4.7
HCO3
-: plasma bicarbonate concentration; PaCO2: partial pressure of carbon dioxide in arterial blood; BE: base excess; tCO2: total carbon dioxide concentration; PaO2:
partial pressure of oxygen in arterial blood; tHb: total haemoglobin concentration; SaO2: arterial oxygen saturation; Na
+: sodium plasma concentration; K+: potassium
plasma concentration; Cl-: chloride plasma concentration; PAO2: alveolar partial pressure of oxygen (= PaO2 x (Patm-47)-1.2 x PaCO2); T+5, T+20, and T+35: 5, 10, and
35 minutes after alfaxalone administration, respectively.
https://doi.org/10.1371/journal.pone.0204553.t002
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Table 3. Mean (± SD) echocardiographic measurements in 12 healthy conscious and alfaxalone-administered (4 mg kg-1 intramuscularly) Beagles.
Variables Baseline Sedation p-value
2D Measurements
CO (L/min) 1.5 ± 0.4 1.4 ± 0.4 p = 0.29
SV (ml) 15 ± 5 11 ± 3 p< 0.001
EDV (ml) 24.7 ± 5.7 19.4 ± 4.9 p< 0.001
ESV (ml) 9.4 ± 1.8 8.5 ± 2.3 p = 0.1
LA diameter (mm) 24.1 ± 2.9 21.1 ± 2.4 p = 0.04
Ao diameter (mm) 18.1 ± 1.7 17.9 ± 1.4 p = 0.67
LA/Ao 1.33 ± 0.11 1.18 ± 0.1 p = 0.01
EF (%) 69.9 ± 7.2 56.3 ± 6.3 p = 0.18
M-Mode echocardiographic
LVIDd (mm) 29.2 ± 2.9 28.2 ± 3.0 p = 0.29
IVSd (mm) 7.5 ± 0.9 7.5 ± 1.6 p = 0.9823
LVPWd (mm) 7.5 ± 1.2 8.0 ± 1.3 p = 0.46
LVIDs (mm) 19.9 ± 3.3 18.7 ± 1.9 p = 0.25
IVSs (mm) 10.3 ± 1.5 10.0 ± 1.6 p = 0.52
LVPWs (mm) 11.0 ± 1.9 9.9 ± 1.2 p = 0.1
FS (%) 31.9 ± 6.5 33.7 ± 4.3 p = 0.52
Doppler echocardiographic measurements
E velocity (m s-1) 0.62 ± 0.09 0.51 ± 0.08 p = 0.007
A velocity (m s-1) 0.38 ± 0.10 0.40 ± 0.14 p = 0.27
E/A 1.75 ± 0.46 1.37 ± 0.37 p = 0.009
EDT (ms) 130.8 ± 27.5 93.0 ± 21.4 p = 0.005
E’lat (ms) 0.14 ± 0.08 0.08 ± 0.02 p = 0.02
A’lat (ms) 0.11 ± 0.09 0.05 ± 0.02 p = 0.04
E’lat/A’lat 1.42 ± 0.52 1.55 ± 0.64 p = 0.44
E’sept (ms) 0.07 ± 0.01 0.05 ± 0.01 p< 0.001
A’sept (ms) 0.05 ± 0.01 0.05 ± 0.02 p = 0.1
E’sept/A’sept 1.40 ± 0.25 1.18 ± 0.41 p = 0.13
E/E’lat 5.28 ± 1.71 7.27 ± 1.81 p = 0.004
E/E’sept 8.75 ± 2.18 11.10 ± 2.32 p = 0.02
IVRT (ms) 74.7 ± 20.4 86.6 ± 12.2 p = 0.18
E/IVRT 0.010 ± 0.007 0.006 ± 0.002 p = 0.1
VAo max (m s
-1) 1.22 ± 0.10 1.01 ± 0.10 p< 0.001
Vpulmmax (m s
-1) 1.1 ± 0.17 0.93 ± 0.20 p = 0.01
Valvular insufficiency
TR 1.97 ± 0.43 1.96 ± 0.33 p = 0.8
PR 0.90 ± 0.17 1.36 ± 0.30 p = 0.01
CO: cardiac output; SV: stroke volume; EDV: left ventricular end-diastolic volume; ESV: left ventricular end-systolic volume; LA: left atrial diameter in early diastole;
Ao: aortic diameter in early diastole; LA/Ao: left atrial diameter to aortic diameter ratio; EF: ejection fraction; LVIDd: left ventricular internal dimension in diastole;
IVSd: interventricular septum in diastole; LVPWd: left ventricular posterior wall in diastole; LVIDs; left ventricular internal dimension in systole; IVSs interventricular
septum in systole; LVPWs: left ventricular posterior wall in systole; FS: fractional shortening; E velocity: peak velocity of early diastolic transmitral flow; A velocity: peak
velocity of late diastolic transmitral flow; EDT: E-wave deceleration; E’ lat: peak early diastolic lateral mitral valve annulus velocity; A’ lat: peak late diastolic lateral mitral
valve annulus velocity; E’ sept: peak early diastolic septal mitral valve annulus velocity; A’ sept: peak late diastolic septal mitral valve annulus velocity; IVRT:
isovolumetric relaxation time; VAo max: peak aortic flow velocity; VPulmmax: peak pulmonic flow velocity.
values are different from Baseline with p< 0.002 (Bonferroni correction: 0.05/24 = 0.002). A local false discovery rate was calculated using 24 variables (excluding the
ratios as composite variables) with a cut-off of 0.01 and obtained the same three variables (EDV, E’sept, and VAo max) that were significantly different with the
Bonferroni correction.
https://doi.org/10.1371/journal.pone.0204553.t003
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sedation. None of the recorded maximum velocities were indicative of systolic and/or diastolic
pulmonary hypertension according to previously published data (> 2.80 m/sec for tricuspid
regurgitation and 2.20 m/sec for pulmonary regurgitation) [22].
Adverse effects
Paddling, trembling and nystagmus were noted in 6 alfaxalone-administered dogs (50%) dur-
ing echocardiography at T+20 (A), at T+2 and T+31 (E), at T+15 and T+17 (G), at T+32 (H),
at T+4, T+22, and T+24 (L), and at T+19 and T+21 (K). External noises excited two of these
dogs (G and L) and the echocardiographic examination had to be paused for a few minutes (at
T+19 and T+24, respectively) in order for them to calm down.
Discussion
To our knowledge, this is the first report on the pharmacokinetics and echocardiographic
effect of IM alfaxalone alone in dogs. In the present study, the IM administration of 4 mg kg-1
of alfaxalone to healthy Beagles induced moderate to deep sedation for 30 minutes and was
associated with a significant increase in HR and a significant decrease in SV, EDV, MAP, fR,
and rectal temperature. The CO and systemic oxygenation remained unchanged after IM
alfaxalone. Adverse reactions such as an increased reactivity to sound, trembling, paddling and
nystagmus were observed during sedation.
Several studies report the cardiovascular effects of alfaxalone administered IV alone in
healthy dogs. They differ in the population, the route of administration, the dose, the type of
qualitative scores used (to assess the quality of induction, neurodepression and recovery) and
the definition of the different times studied (sedation, recovery). However, despite these differ-
ences most of them seem to agree with our findings, indicating that a dose of alfaxalone greater
than 2 mg kg-1 IV induces a dose-dependent increase in HR and a decrease in blood pressure
[3–6].
The tachycardia can be a limiting factor for the use of alfaxalone during echocardiography.
Some authors highlighted that alfaxalone might be contraindicated in patients in whom an
excessive rise in HR could increase the risk of myocardial ischaemia. In addition, an increase
in HR may interfere with acquisition of high quality echocardiographic images. Slow IV
administration was suggested to reduce the short-lived alfaxalone-induced tachycardia [5].
Tamura et al.’s studies [10,12] demonstrated that the haemodynamic effects may be more
moderate with no increase in HR when alfaxalone at doses of 2.5, 5, 7.5 and 10 mg kg-1 was
administered IM. These findings suggested that this administration route might have less dele-
terious effect on the cardiovascular function than the IV route, although this was not con-
firmed by our study. Unfortunately, in Tamura et al.’s studies, the population was small with a
large distribution of age and body weight, which may not have achieved sufficient statistical
power.
In our study, the increase in HR could be associated with the decrease in blood pressure
through the baroreceptor reflex. A decrease in systemic vascular resistance was more likely to
be the mechanism of blood pressure reduction, since CO was maintained by compensatory
responses between HR increase and SV decrease. This was supported by previous studies that
observed an association of IV-alfaxalone-induced tachycardia with either no change in CO [4]
or an increase in cardiac index [5] and a decrease in systemic vascular resistance [4,5]. Addi-
tionally, vasodilatation may have been responsible for the continuous decrease in body tem-
perature, which was also reported in other studies [4,12], and the use of heating devices during
alfaxalone sedation may be advisable.
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The present study identified only minor changes in echocardiographic variables following
IM alfaxalone alone in healthy dogs. The decrease in EDV and E’sept was most likely a direct
consequence of the increased HR, due to the decreased time for ventricular filling during dias-
tole. The decrease in VAo max might have been a consequence of the decrease in EDV. How-
ever, the magnitude of changes in these variables was low and most likely of no clinical
relevant. Accordingly, the IV administration of 3 mg kg-1 alfaxalone in healthy dogs also
showed only clinically insignificant variations in echocardiographic variables and HR [6]. To
our knowledge there are no studies characterizing the echocardiographic effects of an IM
injection of alfaxalone alone in dogs. Seo et al. [23] studied the combination of 2 mg kg-1 alfax-
alone IM with butorphanol and midazolam and showed a non-statistically significant reduc-
tion on echocardiographic left ventricular indices. Lee et al. [11] observed a decrease in HR,
CO, SV, LVEF and FS and an increase in LVIDs following the combination of 2 mg kg-1 alfaxa-
lone IM with butorphanol and medetomidine but the role of each drug on myocardial depres-
sion remained unclear. In cats, the association of butorphanol (0.2 mg kg-1) and alfaxalone (2
mg kg-1) IM induced only a mild decrease in HR. The effects on echocardiographic measure-
ments were not considered clinically relevant except for the reduction in FS and EF, which are
markers of left ventricular function [13]. Studies specifically designed to look at the echocar-
diographic effects of this drug combination in dogs are lacking and might be of high clinical
interest.
In the present study, fR decreased significantly during both simple sedation and sedation
for echocardiography. These results are in accordance with Tamura et al.’s study [10] who
found a significant decrease in fR in dogs after IM alfaxalone administered at 5 mg kg-1, 7.5
mg kg-1, and 10 mg kg-1. Muir et al. [4] also found a dose-dependent decrease in fR and minute
volume immediately after induction with IV alfaxalone at 2 mg kg-1, 6 mg kg-1 and 10 mg kg-1
in dogs. Episodes of apnoea and hypoxemia were observed following the highest doses. In our
study, as well as in Tamura et al.’s study, apnoea was not observed and the decrease in fR had
no effect on arterial blood gas analysis, suggesting it might have been clinically non-significant.
The IV route might induce more severe respiratory depression than the IM route. Decreased
fR was also observed when alfaxalone was used in combination with other sedative drugs [11,
24].
Body temperature decreased slightly with time (loss of 1˚C), which was not surprising dur-
ing anaesthesia. The temperature was negatively associated with the alfaxalone plasma concen-
tration, despite the latter also decreasing with time. These data seemed conflicting but could be
explained if we consider the observation times and duration of the study. The alfaxalone
plasma concentration decreased with time only from T15. However, the greatest temperature
reduction, which was accompanied by the maximal increase in alfaxalone concentration, was
observed within the first 10 minutes after drug administration. The decrease in systemic vascu-
lar resistance induced by alfaxalone could explain the heat loss, which was certainly more
important during the first part of the sedation.
The mean t1/2 (29 ± 8 minutes), Vd (1.94 ± 0.63 L kg-1) and Clp (47.7 ± 14.1 mL kg-1 min-
ute-1) were similar to those published by Ferre´ et al. [13] in Beagles after IV administration of
half of our dose of alfaxalone (2 mg kg-1), i.e. 24.0 ± 1.9 minutes, 2.4 ± 0.9 L kg-1, and
59.4 ± 12.9 mL kg-1 minute-1, respectively. Pasloske et al. [25] also found similar values in
unpremedicated Greyhounds that were administered 2 mg kg-1 alfaxalone IV. These values
indicated a relatively rapid elimination of the molecule and good diffusion in the organism
(large volume of distribution). Ferre´ et al. [14] detected maximum plasma concentrations at 2
minutes after IV injection of 2 mg kg-1 alfaxalone. In our study, the first sampling was with-
drawn at 5 minutes after IM administration to avoid the influence of external stress and to
allow for the animal to become sedated and recumbent. Venous blood samples prior to 5
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minutes after injection would have been necessary to determine the maximum plasma concen-
tration after IM administration. This would have improved the precision of pharmacokinetic
data. Furthermore, additional alfaxalone plasma concentration analysis at least every hour for
three hours, might have allowed to record the time needed to clear the plasma from the drug.
In our study, we wanted to characterize the effects of IM alfaxalone alone on cardiovascular
function. However other authors have suggested that the combination of alfaxalone IM with
other molecules could have many advantages in premedication [11, 12]. The synergic sedative
effect with other drugs produces sparing effects on the dose of IM alfaxalone and reduces the
large volume required to produce clinical sedation compared to alfaxalone alone. It is also
expected that the combination provides analgesia and better quality of anaesthesia and recov-
ery. However, some combinations, such as with medetomidine, were not advisable for patients
with cardiac disease as the beneficial sedative effects are overcome by a significant bradycardia
most likely caused by a baroreceptor mediated reflex associated with the alpha-2 adrenoceptor
agonist [12]. Alfaxalone associated with butorphanol produced good and safe sedation for
echocardiography in cats [13] and, therefore, it might improve the quality of sedation in dogs
without challenging the cardiovascular function.
Based on the sedation scores dogs were moderately to deeply sedated for a period of
approximately 30 minutes, which was just enough for completing the echocardiography. This
observation corresponds to results from Tamura et al. [10] in which dogs treated with 5 mg
kg-1 of alfaxalone IM remained recumbent for 36 ± 28 minutes. Intravenous administration of
4 mg kg-1 alfaxalone produced anaesthesia for 25 ± 7 minutes in healthy Beagles [5]. The
shorter duration of sedation may be explained by the lower, but more sustained, peak plasma
concentrations generally achieved after IM administration in comparison with the IV route. In
our study, only a few dogs reached the maximal sedation score possibly because the dose of
alfaxalone was too low. Indeed, the neurodepression score appears to be dose-dependent [10].
The quality and depth of sedation is difficult to evaluate objectively. The comparison with
other studies is also difficult because they use different sedation scores. In absence of a vali-
dated sedation score for dogs, a composite simple descriptive sedation score modified from
Gurney et al. [20] was chosen to evaluate sedation in our patients. Taking into account posture,
appearance, interactive behaviour, restrainability, response to noise and general attitude, this
subjective score was made to be as discriminating as possible. We expanded the existing score
to include the response to shoulder touch, as used in a sedation score by Smith et al. [26]. It
should be noted that the sedation scores obtained after IM injection have a great individual
variability. This is evident from the wide range of each data (Table 1 and Fig 3) and the large
standard deviation observed in Tamura et al.’s study [10], which were not observed by Rodri-
guez et al.’s [5] following IV administration. Therefore, the precise duration of sedation based
on scores is difficult to estimate.
In our study, times of sedation were similar to those observed by Tamura et al. [10] after
alfaxalone 5 mg kg-1 IM (VFMT: 28 ± 10 minutes vs 26 ± 18 minutes; HLT: 31 ± 8 minutes vs
37 ± 28 minutes, DecT 42 ± 14 minutes vs 36 ± 28 minutes, respectively), except for UST
(48 ± 12 minutes vs 84 ± 31 minutes, respectively) and RecT (16 ± 8 minutes vs 34 ± 8 minutes,
respectively). The difference in UST might result from the definition of “unaided standing”
including or not the period of post standing ataxia. The addition of medetomidine and butor-
phanol to 2.5 mg kg-1 alfaxalone IM doubled the sedation times [12]. Times of sedation (induc-
tion, maintenance, and recovery) are defined differently depending on the study. For example,
some studies define the duration of sedation as the time between lateral recumbency and extu-
bation while others define it as the time between lateral recumbency and first head lift, which
may preclude the comparisons between studies. The duration of sedation defined as the time
from induction to extubation was shorter after IV than IM administration (9.8 ± 2.4 minutes;
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13.8 ± 4.6 minutes; 31.4 ± 6.9 minutes; 75.1 ± 28.9 minutes at 2, 3, 6 and 20 mg kg-1, respec-
tively) [4,6].
Most studies report that the quality of recovery from alfaxalone anaesthesia alone in dogs is
“quite smooth” to “excellent” [4,10,24,27]. However, it was also reported that dogs exhibited
transient muscular tremor, staggering gait, paddling of the forelimb, muscular twitching, limb
extension or vocalization during the early recovery phase [3,10]. Ferchichi et al. [28] suggested
that the dogs were no longer exposed to alfaxalone during the recovery phase from a 50–90
minutes-anaesthesia produced by 2 mg kg-1 alfaxalone IV associated with methadone and that
the excitement observed during recovery could not be considered as a side effect of alfaxalone.
We also observed some of these events in our study and it was suggested that they are more
common when alfaxalone is administered IM as compared with the IV route because of differ-
ences in pharmacokinetics [10]. In our study, the time needed to clear the plasma from the
drug (considering five times the plasma terminal half-life) would be approximatively 2h30,
which is longer than the duration of the sedation. Therefore, the dogs were most likely still
exposed to alfaxalone during the recovery phase as observed in Fig 3. Nevertheless, in accor-
dance with Ferre´ et al.’s [14] observations, the agitation occurred only in response to either
manipulation or sounds during sedation. Further studies would be required to evaluate the
effect of premedication with butorphanol on the quality of sedation and recovery from IM
alfaxalone.
The present study had several limitations. First, the small sample size may have limited the
power of the tests involving echocardiographic measurements. Second, the population studied
was healthy young dogs. As a consequence, this study did not address the safety of administer-
ing alfaxalone IM to dogs with heart disease or old dogs (more representative of the population
of dogs with heart disease). Furthermore, the short duration of sedation did not allow to study
repeated echocardiographic measurements over time. The fact that animals underwent the
experiment in the same order could have created a bias, and a learning curve or an adaptation
of the animals to instrumentation, decreasing or increasing their stress levels, could not be
excluded. For this reason, we compared the results of HR, MAP and fR between the first and
second sedation. Although mean values for all parameters were lower during echocardiogra-
phy than during sedation scoring, the trend was comparable. This suggested that a familiarisa-
tion of the animals to the experimental setting could have occurred thereby decreasing their
stress levels before sedation, but could also have indicated that the drug’s action itself is
responsible for the trend.
Conclusions
Although the duration of sedation achieved with 4 mg kg-1 alfaxalone was sufficient and
changes in the echocardiographic measurements remained limited, IM alfaxalone alone may
not be considered an ideal sedative drug during echocardiography due to its significant influ-
ence on HR. Further studies would be required to evaluate the effect of alfaxalone in dogs with
cardiac diseases and the impact of the association between IM alfaxalone with butorphanol on
the quality of sedation for echocardiography in dogs
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